menu
newsletter
News
2008-10-10Antibacterial clothes may revolutionize hospital and laboratory
fashion.
Technology based on coating the surface of inert particles with nanoparticles of precious metals, specifically silver, and using it for production of hospital and laboratory gowns may become a new trend revolutionizing septic standards. Highly reactive nanoparticles are known for their bactericidal, viricidal and fungicidal features. Scientists from Department of Chemical Technology of Gdansk University of Technology use those particles to construct novel, antibacterial fabric.
Polfa Tarchomin fights for its survival
Polish Pharmaceutical Holding (PHF) is a mistake - claim NIK (Supreme Chamber of Control) and MSP (Ministry of Treasury). The company survived another year despite the decision to sell all three Polfa which belong to the holding.
Tarchomin Polfa, the weakest financial holding company, is struggling again. Pekao SA, a Polish bank, which passed Polfa’s 40 mln PLN credit line.
There are ongoing negotiations on signing a new contract. The Bank expectations are “fairly drastic” – said Henry Wozniak, PHF CEO.
The situation is further complicated by the fact that the owner of Pekao SA - Italian UniCredit - found himself in trouble as a result of the collapse of financial markets.
Polish biotechnology develops wings and enters the international arena.
Recently announced participation of Poles in the Swedish seminar, will accompany the 4th BIO-Angstrom Conference New Diagnostics - Needs, Demands and Technical Solutions, proves increasing significance of Polish biotechnology in the international arena. It appears, however, that Polish biotechnology has also sought to be overseas. Representatives of Poland are going to Bio International Convention 2009 in Atlanta. It's the biggest international event, gathering leaders of world biobusiness and biotechnology.
2008-10-08TEVA Pharmaceuticals Poland launches new drug
As part of modern technology transfer to the production of drugs to Poland, TEVA Pharmaceuticals Poland is produces montelukast, a modern drug for asthma treatment, called DRIMON.
Montelukast, in accordance with international guidelines is commonly used
in the treatment of patients suffering from mild to moderate severity asthma
who do not have a sufficient disease control by a standard treatment (mainly inhaled corticosteroids). This medicine is also used by patients suffering from asthma and simultaneous seasonal allergic rhinitis. It helps to prevent the occurrence of symptoms of asthma caused by exercises.
Polish vaccines against Enterobacteriacea, Salmonella and Shigella.
Prof. Andrzej Gamian, one of the leading Polish scientists, is focused on infectious diseases and is working on development of new vaccines against bacteria. His laboratory belongs toL. Hirszfeld’s Institute of Immunology and Experimental Therapy (Polish Academy of Sciences) in Wroclaw. Prof. Gamian's group is focused on bacterial wall compounds, like glycolipids, lipopolisacharydes and bacterial surface proteins. This research will hopefully result in improvement of control over infectious diseases.
Hasco-Lek is going to open a new plant.
In the beginning of October the board of Hasco-Lek put the foundation-stone in place where the new factory is being built – Siechnice near Wroclaw (Poland). The investment will cost around 73 mln PLN (21.2 mln EUR).
Lack of the expansion possibility of the present Hasco-Lek factory caused the decision to purchase a plot for the new plant. The executive board decided that new factory will be located in Industrial Activity Zone in Siechnice. The construction works started in July 2008 and are planning to be finished in next year coinciding with the 25th anniversary of Hasco-Lek activity.
Antibiotice invests 8m euros in production
Drug producer Antibiotice Iasi, one of the leading players in the industry, has budgeted investments worth 7.5-8 million euros to expand the tablet manufacturing capacity in the 2008 - 2009 period, from 250 to 500 million units per year. "The new department will become operational in the last quarter of 2009, and we would like to secure the necessary authorisations from the FDA (Food and Drug Administration, the regulatory authority in the US) in order to export to the USA," said Coca Cascaval, general manager of Antibiotice.
Polish and foreign investors are interested in privatization of Polfa Tarchomin, Polfa Pabianice and Polfa Warszawa.
"Polish and foreign investors are submitting their interest in privatization of three Polfas. There are four or five Among those investors are Adamed and a transactor from USA." – said Jan Bury, vice-Minister of treasury Treasury.
Accordind to previous PAP informations, owned by the Polish Misistry of the Treasury Pharmaceutical Holding (PHF) is planning to sell all Polfas by the end of 2009 to consortia or investors from the branch.
UPDATE 1-EU says Zentiva/Sanofi deal notification incomplete
The notification to EU competition regulators of plans by French pharmaceuticals producer Sanofi-Aventis to buy Czech generic drugmaker Zentiva is incomplete, the European Commission said.
The companies will have to renotify the EU executive and then a new deadline for the Commission's competition review will be set, a Commission spokesman said on Friday.
After many months of decreasing stocks value Bioton started its recovery. Investors hope for Polpharma support.
Bioton quotations, even though unstable in the last week, allowed investors to save their profits gained during last few sessions. Between September 17 and 25 Bioton stocks value increased of 17,5% (from 0.40 to 0.47 PLN) therefore Bioton quotations have reached the highest price since June.
